[1] Chen S, Cao Q, Wen W, et al. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
[J]. Cancer Letters, 2019, 460: 1-9.

[2] Cheng A-L, Hsu C, Chan S L, et al. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
[J]. Journal of Hepatology, 2020, 72(2): 307-319.

[3] Wei S C, Duffy C R, Allison J P. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
[J]. Cancer Discovery, 2018, 8(9): 1069-1086.

[4] Butte M J, Keir M E, Phamduy T B, et al. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses
[J]. Immunity, 2007, 27(1): 111-122.

[5] El-Khoueiry A B, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
[J]. The Lancet, 2017, 389(10088): 2492-2502.

[6] Yau T, Park J W, Finn R S, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
[J]. Annals of Oncology, 2019, 30: v874-v875.

[7] Zhu A X, Finn R S, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
[J]. The Lancet Oncology, 2018, 19(7): 940-952.

[8] Sangro B, Gomez-Martin C, De La Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
[J]. Journal of Hepatology, 2013, 59(1): 81-88.

[9] Fife B T, Bluestone J A. Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
[J]. Immunological Reviews, 2008, 224(1): 166-182.

[10] Kaseb A O, Hasanov E, Cao H S T, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
[J]. The Lancet Gastroenterology & Hepatology, 2022, 7(3): 208-218.

[11] Kelley R K, Sangro B, Harris W, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
[J]. Journal of Clinical Oncology, 2021, 39(27): 2991-3001.

[12] Wolf Y, Anderson A C, Kuchroo V K. TIM3 comes of age as an inhibitory receptor
[J]. Nature Reviews Immunology, 2020, 20(3): 173-185.

[13] Lichtenegger F S, Rothe M, Schnorfeil F M, et al. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
[J]. Frontiers in Immunology, 2018, 9: 385.

[14] Lee M S, Ryoo B-Y, Hsu C-H, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
[J]. The Lancet Oncology, 2020, 21(6): 808-820.

[15] Finn R S, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
[J]. New England Journal of Medicine, 2020, 382(20): 1894-1905.

[16] Finn R S, Ikeda M, Zhu A X, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
[J]. Journal of Clinical Oncology, 2020, 38(26): 2960-2970.

[17] Li L, Wu P-S, Liang X-M, et al. Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study
[J]. Journal of Gastroenterology, 2023, 58(10): 1043-1054.

[18] Xu J, Zhang Y, Jia R, et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
[J]. Clinical Cancer Research, 2019, 25(2): 515-523.

[19] Xu J, Shen J, Gu S, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
[J]. Clinical Cancer Research, 2021, 27(4): 1003-1011.

[20] Qin S, Bai Y, Lim H Y, et al. Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
[J]. Journal of Clinical Oncology, 2013, 31(28): 3501-3508.

[21] Li H, Qin S, Liu Y, et al. Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study
[J]. Drug Design, Development and Therapy, 2021, Volume 15: 1873-1882.

[22] El Dika I, Khalil D N, Abou‐Alfa G K. Immune checkpoint inhibitors for hepatocellular carcinoma
[J]. Cancer, 2019, 125(19): 3312-3319.

[23] Marinelli B, Kim E, D'Alessio A, et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
[J]. J Immunother Cancer. 2022, 10(6):e004205.

[24] Pan X, Wu S-J, Tang Y, et al. Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
[J]. Journal of Hepatocellular Carcinoma, 2023, Volume 10: 883-892.

[25] Chiang C L, Chiu K W H, Chan K S K, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial
[J]. The Lancet Gastroenterology & Hepatology, 2023, 8(2): 169-178.

[26] Li J-X, Su T-S, Gong W-F, et al. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial
[J]. Hepatology International, 2022, 16(5): 1179-1187.

[27] Duffy A G, Ulahannan S V, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
[J]. Journal of Hepatology, 2017, 66(3): 545-551.

[28] Lyu N, Kong Y, Li X, et al. Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study
[J]. Frontiers in Oncology, 2020, 10: 580241.